Healthcare will require a new approach and tools to support new patient expectations in 2020. A patient-centric approach to healthcare will be more relevant than ever. Covid-19 has uncovered new challenges and weaknesses in care that are dependent on a centralized set-up. What is becoming more and more clear is that diagnostic labs need to evolve and up their game to stay relevant. This will continue to bring value to patients throughout the healthcare journey. A key focus in 2021 will be taking a look at building and maintaining better relationships between private and public players in patient care.

1. Tomorrow’s Lab Today:
Focus areas for medical
biology and diagnostic
testing in 2021
Based on in-depth reporting taken from surveys
with healthcare professionals and patients and
interviews with biologists

2. New expectations require new tools
Healthcare will
require a new
approach and tools
to support new
patient expectations
in 2020.
A patient-centric
approach to
healthcare will be
more relevant than
ever.
Covid-19 has
uncovered new
challenges and
weaknesses in care
that are dependent
on a centralized
set-up.

3. Expanding our worldview of patient care
What is becoming
more and more clear
is that diagnostic labs
need to evolve and
up their game to
stay relevant.
This will continue to
bring value to
patients throughout
the healthcare
journey.
A key focus in 2021
will be taking a look
at building and
maintaining better
relationships
between private and
public players in
patient care.

4. A future augmented and
enabled by technology

5. Tomorrow’s Lab Today:
Focus areas for 2021
1. Proximity to the patient
Higher demands for digital tools and an
increased need for telehealth services
2. Public and private collaboration
Real interoperability to drive
accessibility through digitization
3. Decentralized medical biology
Expanded views of patient care with the
home as an extension of the lab
4. New business models
Opportunity to add more value and
create stronger differentiation

6. Proximity to
the Patient
There is a lack of understanding
of the profession of the medical
biologist by the majority of
people.
“
”

7. Public / Private
Collaboration
There is friction and conflict where
there should be complementarity.
Covid-19 has proven there is no
room for luxury for politics.
”
“

8. Decentralized
Medical Biology
There is an opportunity to
“unbundle the lab” by keeping
an open mind about where
patient care takes place,
expanding our view of
treatment. ”
“

9. New Business
Models
Labs have an opportunity to
add more value, create stronger
differentiation, and unlock new
business models.
”
“

10. This report has been developed by
Medicus AI, a leading technology
company supporting the diagnostic
testing partners with an innovative
digital health solution.
We embarked on this study to better
assess and understand the challenges
facing medical biologists and the
healthcare industry, and to identify
solutions to support a new era of
healthcare.
The research included over 2,200 survey
participants, and almost 20 expert
interviews, and was completed in
December 2020.
About this report

11. Medicus is a leading technology company
supporting the diagnostic industry with an
innovative digital health solution.
Medicus’ licensed, integrated, and
white-labeled B2B2C platform empowers
users to visualize and interpret health data
from blood tests and medical reports,
helping patients and users better
understand and manage their health.
Medicus works with some of the largest
providers in Europe and the Middle East,
delivering solutions and supporting specific
use cases, with a combined patient reach of
30 million and growing.
About Medicus

12. More about Medicus
Austria • Germany • France • China • UAE • Lebanon • Switzerland
● Licensed, integrated, and
white-labeled B2B2C
platform
● Founded in 2016
● Presence in 7 countries
● 100+ employees
● 30m+ patients covered by
our products today

13. Methodology
● Le Biologiste Augmenté (LBA) was undertaken to better understand the challenges and
needs of the biology community in France in partnership with Roche Diagnostics (France).
● For the 2020 edition, the second edition of the initiative, we sought to draw some parallels
between the evolution of the profession with a major crisis.
● The LBA sessions were undertaken to better understand the challenges and needs of the
medical biology and diagnostic lab community in France.
● The research included interviews with key opinion leaders in the healthcare sector in France
including the president of the union of biologists, experts in artificial intelligence, liberal and
public biologist, etc.
● We received more than 2,200 responses to an online survey, allowing us to obtain quantitative
elements on some of the questions we asked ourselves.
● For more information, or to download the full report (currently available in French), please visit
lebiologisteaugmente.com or send an email to LBA@medicus.ai

14. Dr. Baher Al Hakim, CEO
Medicus AI
baher@medicus.ai